TCM
ACET icon

Tang Capital Management’s Adicet Bio ACET Stock Holding History

Tang Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,158
Closed -$51.9K – 53
2025
Q4 		$51.9K Sell
6,158
-507,818
-99% -$5.61M ﹤0.01% 73
2025
Q3 		$6.66M Hold
513,976
– – 0.26% 84
2025
Q2 		$5.02M Hold
513,976
– – 0.25% 83
2025
Q1 		$6.21M Buy
513,976
+4,852
+1% +$69.4K 0.34% 67
2024
Q4 		$7.84M Sell
509,124
-4,436
-0.9% -$83.7K 0.52% 52
2024
Q3 		$11.8M Hold
513,560
– – 0.85% 40
2024
Q2 		$9.94M Buy
513,560
+113,097
+28% +$3.03M 1.01% 32
2024
Q1 		$15.1M Buy
400,463
+345,691
+631% +$14.3M 1.57% 20
2023
Q4 		$1.66M Sell
54,772
-21,875
-29% -$477K 0.15% 98
2023
Q3 		$1.68M Sell
76,647
-78,325
-51% -$2.77M 0.24% 76
2023
Q2 		$6.03M Sell
154,972
-2,528
-2% -$223K 0.89% 34
2023
Q1 		$14.5M Buy
157,500
+120,000
+320% +$15.1M 2.16% 15
2022
Q4 		$5.36M Buy
+37,500
New +$9.36M 0.78% 33

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Tang Capital Management's ACET Position: Q1 2026 in Review

Tang Capital Management sold out of Adicet Bio (ACET) in Q1 2026, closing a stake of 6,158 shares — an estimated $51.9K sold.

Tang Capital Management first reported a position in ACET in Q4 2022 and held it in 13 quarters. The position peaked at $15.1M in Q1 2024. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • Tang Capital Management reported no remaining Adicet Bio position as of Q1 2026 after selling out during the quarter.
  • Tang Capital Management sold 6,158 Adicet Bio shares in Q1 2026, an estimated $51.9K.
  • Tang Capital Management first reported a position in Adicet Bio in Q4 2022 and held it in 13 quarters.
  • Tang Capital Management's Adicet Bio position peaked at $15.1M in Q1 2024.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Tang Capital Management's 13F filing for Q1 2026, filed 15 May 2026.